An interventional study of blood sample and Pulse wave velocity in Hereditary Spherocytosis, sponsored by Hospices Civils de Lyon. Completed at 2 sites in France. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science
Background : Patients with hereditary spherocytosis (HS) are characterized by increased red blood cell (RBC) fragility and a loss of RBC deformability. While the clinical variability of the disease may be heterogenous from one patient to another, some studies reported the occurrence of vascular complications, notably in patients who have been splenectomized.
Purpose : The aim of the study is to test the associations between the degree of vascular dysfunction and the extent of hemolysis, the amount of circulating microparticles, the level of erythrosis and the degree of RBC biophysical alterations.
Abstract : Recent studies reported the occurrence of vascular complications in patients with HS, notably in patients who have previously been splenectomized. However, the exact reasons of these complications are unknown and no study investigated the vascular function in HS patients.
Main objective Highlight the presence of altered vascular function in HS patients and test the relationships with the level of hemolysis and circulating microparticles.
Secondary objectives To evaluate the associations between clinical severity and 1) the level of vascular dysfunction and 2) several biomarkers (hemolysis, hematological parameters, circulating microparticles, erythrosis, RBC biophysical properties).
120 studies on the registry are indexed under Hemolysis; 22 are open to participants now.
This study's enrollment of 72 is above the median of 49 across 78 interventional studies indexed under Hemolysis.
Browse Hemolysis studies →Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy controls:
Patients with hereditary spherocytosis:
Exclusion Criteria:
Healthy controls:
Patients with hereditary spherocytosis:
20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.
Biological: blood sample · Diagnostic Test: Pulse wave velocity
60 patients with hereditary spherocytosis will be included in this study.
Biological: blood sample · Diagnostic Test: Pulse wave velocity
6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
measurement of pulse wave velocity (PWV)
Vascular function (arterial stiffness) will be investigated by the measurement of pulse wave velocity (PWV). Vascular dysfunction will be defined by a PWV value higher than 6 meter/second (m/s) and 10 m/s in children and adults with HS, respectively.
Time frame: Day 1
Hemogram
The hemogram is a complete blood count of the different cell types. All these measures are performed simultaneously on a standard hematology analyzer.
Time frame: Day 1
Markers of hemolysis
These markers are measured simultaneously on a standard biochemistry analyzer
Time frame: Day 1
Circulating microparticles
Circulating microparticles of various cell origin will be measured by flow cytometry
Time frame: Day 1
Markers of erythrosis
Markers of erythrosis (i.e., suicidal death of red blood cells) will be measured by flow cytometry
Time frame: Day 1
Blood viscosity
Blood viscosity (expressed in Pa.s) will be measured on a cone-plate viscosimeter, ektacytometry and light transmission, respectively.
Time frame: Day 1
Red blood cell deformability
Red blood cell deformability will be measured simultaneously on a Lorrca ektacytometry (Laser-assisted Rotational Red Cell Analyser).
Time frame: Day 1
Red blood cell aggregation
Red blood cell aggregation will be measured simultaneously on a Lorrca ektacytometry (Laser-assisted Rotational Red Cell Analyser).
Time frame: Day 1
Ran from Aug 2020 to primary completion in Aug 2022, 24 months.
Of 28 interventional studies with no phase under Hemolysis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 35. This study's 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.